The FY19 Defense Appropriation provides $130 million to the Department of Defense Breast Cancer Research Program to support innovative, high-impact research with clinical relevance that will accelerate progress to end breast cancer for Service members, Veterans, and the general public. FY19 BCRP Program Announcements and General Application Instructions for the following award mechanisms are posted...
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
